ADAM9 and hepatocellular carcinoma: Besides the STING/TBK1 pathway revealed in this study, recent research has shown that factors such as ADAM9 can modulate the HCC immune microenvironment through regulation of ferroptosis.[46]While previous studies have demonstrated that hyperactivation of this pathway may induce benign liver injury through pro‐inflammatory cytokine release,[47] the pathway activation observed in our study is maintained within therapeutic windows, with its critical contribution to antitumor immunity significantly exceeding potential adverse effects.